Stimulating effect of normal-dosing of fibrates on cell proliferation: word of warning

Table 2 Ratio of Ki-67, cyclin E, cyclin A, and Cdc25A positive cells in tested cell lines obtained by immunocytochemistry

	antigen	Ki-67	cyclin E		cyclin A		Cdc25A
	treatment	max. viability (% of positive cells)	max. viability (% of positive cells)	IC10 (% of positive cells)	max. viability (% of positive cells)	IC10 (% of positive cells)	max. viability (% of positive cells)	IC10 (% of positive cells)
HEK293	control	73.44 ± 6.39	56.82 ± 9.68		55.19 ± 4.00		57.25 ± 9.14
	fenofibrate	95.04 ± 7.49	82.11 ± 3.58	73.39 ± 9.26	44.99 ± 0.62	53.49 ± 5.40	37.04 ± 7.65	22.82 ± 8.84
	bezafibrate	91.31 ± 6.83	77.95 ± 2.39	70.33 ± 8.29	46.35 ± 0.05	56.41 ± 0,42	40.23 ± 4.80	22.79 ± 10.74
	gemfibrozil	98.82 ± 0.45	74.42 ± 2.46	62.89 ± 2.15	46.98 ± 2.30	49.83 ± 5.31	47.03 ± 2.94	23.79 ± 7.75
HepG2	control	77.59 ± 1.81	46.65 ± 7.69		34.22 ± 6.06		48.70 ± 6.71
	fenofibrate	83.14 ± 7.05	65.67 ± 3.35	65.21 ± 29.03	42.55 ± 2.23	33.08 ± 3.49	44.92 ± 5.65	40.56 ± 6.81
	bezafibrate	80.82 ± 5.77	59.60 ± 2.33	62.2 ± 8.86	41.59 ± 0.23	38.09 ± 12.48	40.45 ± 5.12	23.92 ± 7.96
	gemfibrozil	82.39 ± 5.54	55.08 ± 2.31	61.57 ± 3.08	47.04 ± 3.72	45.43 ± 4.03	39.94 ± 9.19	24.63 ± 7.98
HT-29	control	72.83 ± 4.33	15.69 ± 1.39		18.39 ± 2.82		57.66 ± 9.41
	fenofibrate	85.96 ± 5.09	24.07 ± 1.02	44.34 ± 6.62	20.36 ± 2.53	59.45 ± 13.84	39.53 ± 4.00	10.60 ± 9.70
	bezafibrate	94.37 ± 1.07	21.64 ± 2.04	39.38 ± 12.53	19.53 ± 1.32	53.23 ± 6.14	43.77 ± 8.44	35.88 ± 8.40
	gemfibrozil	90.59 ± 0.88	23.02 ± 2.25	42.64 ± 11.07	18.65 ± 1.13	38.70 ± 21.33	51.13 ± 6.97	46.26 ± 4.32

We evaluated % of positive cells in 3 different fields of vision for these antigens in control and fibrates treated HEK293, HepG2, and HT-29 cell lines. Cells were treated by maximal viability and IC10 concentrations of used fibrates. Results are shown as % of positive cells ± SD (n = 3)

ISSN: 1476-511X